267 related articles for article (PubMed ID: 18600415)
1. Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography: a preliminary report.
Terauchi T; Murano T; Daisaki H; Kanou D; Shoda H; Kakinuma R; Hamashima C; Moriyama N; Kakizoe T
Ann Nucl Med; 2008 Jun; 22(5):379-85. PubMed ID: 18600415
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of whole-body cancer screening with multiple modalities including [18F]fluorodeoxyglucose positron emission tomography in a healthy population: a preliminary report.
Nishizawa S; Kojima S; Teramukai S; Inubushi M; Kodama H; Maeda Y; Okada H; Zhou B; Nagai Y; Fukushima M
J Clin Oncol; 2009 Apr; 27(11):1767-73. PubMed ID: 19255324
[TBL] [Abstract][Full Text] [Related]
3. Cancer screening with FDG-PET.
Ide M
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):23-7. PubMed ID: 16557201
[TBL] [Abstract][Full Text] [Related]
4. The value of 18F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening.
Shen YY; Su CT; Chen GJ; Chen YK; Liao AC; Tsai FS
Neoplasma; 2003; 50(3):217-21. PubMed ID: 12937856
[TBL] [Abstract][Full Text] [Related]
5. FDG-PET/CT detection of very early breast cancer in women with breast microcalcification lesions found in mammography screening.
Peng NJ; Chou CP; Pan HB; Chang TH; Hu C; Chiu YL; Fu TY; Chang HT
J Med Imaging Radiat Oncol; 2015 Aug; 59(4):445-452. PubMed ID: 25872026
[TBL] [Abstract][Full Text] [Related]
6. Improved detection of breast cancer on FDG-PET cancer screening using breast positioning device.
Kaida H; Ishibashi M; Fujii T; Kurata S; Ogo E; Tanaka M; Hayabuchi N
Ann Nucl Med; 2008 Feb; 22(2):95-101. PubMed ID: 18311533
[TBL] [Abstract][Full Text] [Related]
7. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer.
Sakurai Y; Kawai H; Iwano S; Ito S; Ogawa H; Naganawa S
J Med Imaging Radiat Oncol; 2013 Jun; 57(3):297-305. PubMed ID: 23721138
[TBL] [Abstract][Full Text] [Related]
8. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L
Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042
[TBL] [Abstract][Full Text] [Related]
9. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of both PET/CT with F18-FDG and whole-body diffusion-weighted imaging in cancer screening: a preliminary report.
Sasamori H; Uno K; Wu J
Ann Nucl Med; 2019 Feb; 33(2):78-85. PubMed ID: 30298377
[TBL] [Abstract][Full Text] [Related]
11. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
12. [Cancer screening with PET: advantages and limitations].
Kawada S; Suzuki Y; Hinohara S; Koide S; Ono Y; Ashikaga H
Rinsho Byori; 2007 Jul; 55(7):656-67. PubMed ID: 17718062
[TBL] [Abstract][Full Text] [Related]
13. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey.
Minamimoto R; Senda M; Uno K; Jinnouchi S; Iinuma T; Ito K; Okuyama C; Oguchi K; Kawamoto M; Suzuki Y; Tsukamoto E; Terauchi T; Nakashima R; Nishio M; Nishizawa S; Fukuda H; Yoshida T; Inoue T
Ann Nucl Med; 2007 Nov; 21(9):481-98. PubMed ID: 18030580
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of 18F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy.
Shoda H; Kakugawa Y; Saito D; Kozu T; Terauchi T; Daisaki H; Hamashima C; Muramatsu Y; Moriyama N; Saito H
Br J Cancer; 2007 Dec; 97(11):1493-8. PubMed ID: 18040274
[TBL] [Abstract][Full Text] [Related]
16. Colorectal cancer screening in asymptomatic adults: the role of FDG PET scan.
Chen YK; Kao CH; Liao AC; Shen YY; Su CT
Anticancer Res; 2003; 23(5b):4357-61. PubMed ID: 14666651
[TBL] [Abstract][Full Text] [Related]
17. Cancer screening of healthy volunteers using whole-body 18F-FDG-PET scans: The Nishidai clinic study.
Kojima S; Zhou B; Teramukai S; Hara A; Kosaka N; Matsuo Y; Suzuki H; Torigoe S; Suzuki T; Uno K; Fukushima M
Eur J Cancer; 2007 Aug; 43(12):1842-8. PubMed ID: 17614273
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
Han A; Xue J; Hu M; Zheng J; Wang X
Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
[TBL] [Abstract][Full Text] [Related]
19. The role of 18F-fluorodeoxyglucose positron emission tomography in cancer screening - a preliminary report.
Kao CH; Kwan AS; Kwan JK; Chow MJ
Oncol Rep; 2001; 8(5):1145-8. PubMed ID: 11496332
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic accuracy of FDG-PET cancer screening in asymptomatic individuals: use of record linkage from the Osaka Cancer Registry.
Sengoku T; Matsumura K; Usami M; Takahashi Y; Nakayama T
Int J Clin Oncol; 2014 Dec; 19(6):989-97. PubMed ID: 24481919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
